2017版WHO垂体非神经内分泌肿瘤分类临床指导及国际疾病分类法编码分析

doi:10.3969/j.issn.1672-6731.2022.02.010

摘要/Abstract

摘要： 2017年世界卫生组织（WHO）发布第四版内分泌肿瘤分类，详细介绍新的肿瘤分类标准及病理分型。2021年5月，WHO更新国际疾病分类法（ICD）即ICD-11，对肿瘤进行丰富的独立附加编码。本文简述垂体非神经内分泌肿瘤，包括颅咽管瘤、神经元和神经元旁肿瘤、神经垂体肿瘤、间叶细胞瘤和间质瘤、淋巴样肿瘤、生殖细胞肿瘤、鞍区继发恶性肿瘤，并结合ICD-10、ICD-11和ICD-O列出相应的疾病编码和形态学编码，根据ICD-11列出每种肿瘤的附加编码。

关键词: 垂体肿瘤, 世界卫生组织, 国际疾病分类法, 综述

Abstract: The fourth edition of the latest classification principles for endocrine tumors was published by the World Health Organization (WHO) in 2017. The latest tumor classification and new pathological classification of each pituitary gland tumor were given in detail. In May 2021, International Classification of Disease-11 (ICD-11) was updated and the independent additional code of each type of tumor was enriched. Non-neuroendocrine tumors, including craniopharyngioma, neuronal and paraneuronal tumors, tumors of posterior pituitary, mesenchymal and stromal tumors, hematolymphoid tumors, germ cell tumors, and secondary tumors in the pituitary gland are described. The corresponding disease codes and morphological codes are listed in combination with ICD-10, ICD-11 and ICD-O. Detailed additional codes for each tumor are listed according to ICD-11.

Key words: Pituitary neoplasms, World Health Organization, International classification of diseases, Review

关宏, 李志红, 孙吉瑞, 贺建辉, 张丽娜. 2017版WHO垂体非神经内分泌肿瘤分类临床指导及国际疾病分类法编码分析[J]. 中国现代神经疾病杂志, 2022, 22(2): 116-125.

GUAN Hong, LI Zhi-hong, SUN Ji-rui, HE Jian-hui, ZHANG Li-na. The 2017 WHO classification and International Classification of Disease coding analysis of non-neuroendocrine tumors in the pituitary gland[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2022, 22(2): 116-125.

https://journal11.magtechjournal.com/cjcnn/CN/Y2022/V22/I2/116

参考文献

[1] Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs[M]. 4th ed. Lyon:IARC Press, 2017:46-63.
[2] ICD-11 for Mortality and Morbidity Statistics. International classification of diseases 11th revision[EB/OL]. 2021-05[2021-05]. https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/1417669099.
[3] Picó A, Aranda-López I, Sesmilo G, Toldos-González Ó, Japón MA, Luque RM, Puig-Domingo M. Recommendations on the pathological report of pituitary tumors:a consensus of experts of the Spanish Society of Endocrinology and Nutrition and the Spanish Society of Pathology[J]. Endocrinol Diabetes Nutr (Engl Ed), 2021, 68:196-207.
[4] International statistical classification of diseases and health-related problems[M]. Dong JW, trans. 2nd ed. Beijing:People's Medical Publishing House, 2008:146-210[.疾病和有关健康问题的国际统计分类[M]. 董景五, 译. 2版. 北京:人民卫生出版社, 2008:146-210.]
[5] Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. International classification of diseases for oncology (ICD-O)[M]. 3rd ed. Geneva:World Health Organization, 2013:71-83.
[6] Müller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera JP, Puget S. Craniopharyngioma[J]. Nat Rev Dis Primers, 2019, 5:75.
[7] Hu W, Qiu B, Mei F, Mao J, Zhou L, Liu F, Fan J, Liu Y, Wen G, Qi S, Bao Y, Pan J. Clinical impact of craniopharyngioma classification based on location origin:a multicenter retrospective study[J]. Ann Transl Med, 2021, 9:1164.
[8] Jastania RA, Saeed M, Al-Khalidi H, AlQuthami K, Nageeti TH, Al-Allaf FA, Valerie K, Taher MM. Adamantinomatous craniopharyngioma in an adult:a case report with NGS analysis[J]. Int Med Case Rep J, 2020, 13:123-137.
[9] Tariq MU, Din NU, Ahmad Z, Memon W. Papillary craniopharyngioma:a clinicopathologic study of a rare entity from a major tertiary care center in Pakistan[J]. Neurol India, 2017, 65:570-576.
[10] Corrêa JAP, Diniz LT, Stavale JN, Kitamura FC, Tibana LAT, Duarte ML, Freitas LF. A rare case of intraventricular gangliocytoma[J]. Arq Neuropsiquiatr, 2022.[Epub ahead of print]
[11] Lopes MB, Sloan E, Polder J. Mixed gangliocytoma-pituitary adenoma:insights on the pathogenesis of a rare sellar tumor[J]. Am J Surg Pathol, 2017, 41:586-595.
[12] Lee SJ, Bui TT, Chen CH, Lagman C, Chung LK, Sidhu S, Seo DJ, Yong WH, Siegal TL, Kim M, Yang I. Central neurocytoma:a review of clinical management and histopathologic features[J]. Brain Tumor Res Treat, 2016, 4:49-57.
[13] Xu L, Ouyang Z, Wang J, Liu Z, Fang J, Du J, He Y, Li G. A clinicopathologic study of extraventricular neurocytoma[J]. J Neurooncol, 2017, 132:75-82.
[14] Lyne SB, Polster SP, Fidai S, Pytel P, Yamini B. Primary sellar paraganglioma:case report with literature review and immunohistochemistry resource[J]. World Neurosurg, 2019, 125:32-36.
[15] Kim DG, Heo YJ, Kim EK, Baek JW, Jeong HW, Jung HS. A primary sellar neuroblastoma mimicking a pituitary adenoma:a case report[J]. J Korean Soc Radiol, 2016, 75:450-454.
[16] Oyama K, Yamada S, Usui M, Kovacs K. Sellar neuroblastoma mimicking pituitary adenoma[J]. Pituitary, 2005, 8:109-114.
[17] Yamamuro S, Fukushima T, Yoshino A, Yachi K, Ogino A, Katayama Y. Primary sellar neuroblastoma in an elderly patient:case report[J]. NMC Case Rep J, 2014, 2:57-60.
[18] Guerrero-Pérez F, Marengo AP, Vidal N, Iglesias P, Villabona C. Primary tumors of the posterior pituitary:a systematic review[J]. Rev Endocr Metab Disord, 2019, 20:219-238.
[19] Louis DN, Ohgaki H, Wiestier OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, von Deimling A. WHO classification of tumours of the central nervous system[M]. 4th ed. Lyon:International Agency for Research on Cancer, 2016:247-264.
[20] Lacruz CR,Saénz de Santamaría J,Bardales RH. Nerve sheath tumors of the craniospinal axis[J]. Cent Nerv Sys Intraop Cytopathol, 2018, 13:283-300.
[21] Kong X, Wu H, Ma W, Li Y, Yang Y, Xing B, Wei J, Yao Y, Gao J, Lian W, Xu Z, Dou W, Ren Z, Su C, Wang R. Schwannoma in sellar region mimics invasive pituitary macroadenoma:literature review with one case report[J]. Medicine (Baltimore), 2016, 95:e2931.
[22] Poudel H, Bhandari R, Khambu BK, Shrestha R, Bista P. Schwannoma presenting as pituitary macroadenoma:case report[J]. Nepal J Neurosci, 2019, 16:59-62.
[23] Sharifnia T, Wawer MJ, Chen T, Huang QY, Weir BA, Sizemore A, Lawlor MA, Goodale A, Cowley GS, Vazquez F, Ott CJ, Francis JM, Sassi S, Cogswell P, Sheppard HE, Zhang T, Gray NS, Clarke PA, Blagg J, Workman P, Sommer J, Hornicek F, Root DE, Hahn WC, Bradner JE, Wong KK, Clemons PA, Lin CY, Kotz JD, Schreiber SL. Small-molecule targeting of brachyury transcription factor addiction in chordoma[J]. Nat Med, 2019, 25:292-300.
[24] Bai J, Li M, Shi J, Jing L, Zhai Y, Zhang S, Wang J, Zhao P, Li C, Gui S, Zhang Y. Mid-term follow-up surgical results in 284 cases of clival chordomas:the risk factors for outcome and tumor recurrence[J]. Neurosurg Rev, 2021.[Epub ahead of print]
[25] Nunes FB, Sant'Ana MSP, Silva AMB, Agostini M, Silva Canedo NH, de Andrade BAB, Romañach MJ, Corrêa DL, Tomasi RA, Radhakrishnan R, Gomez RS, de Sousa SF, Brennan PA, Fonseca FP. Solitary fibrous tumour of the oral cavity:an update[J]. J Oral Pathol Med, 2020, 49:14-20.
[26] Ghanchi H, Patchana T, Christian E, Li C, Calayag M. Pediatric sellar solitary fibrous tumor/hemangiopericytoma:a rare case report and review of the literature[J]. Surg Neurol Int, 2020, 11:238.
[27] Hasanov R, Aydoğan Bİ, Kiremitçi S, Erden E, Güllü S. The prognostic roles of the Ki-67 proliferation index, P53 expression, mitotic index, and radiological tumor invasion in pituitary adenomas[J]. Endocr Pathol, 2019, 30:49-55.
[28] Liu JK, Sayama C, Chin SS, Couldwell WT. Extranodal NK/T-cell lymphoma presenting as a pituitary mass:case report and review of the literature[J]. J Neurosurg, 2007, 107:660-665.
[29] Caputo M, Prencipe N, Bisceglia A, Bona C, Maccario M, Aimaretti G, Grottoli S, Gasco V. Primary pituitary lymphoma as rare cause of a pituitary mass and hypopituitarism in adulthood[J]. Endocr Pract, 2020, 26:1337-1350.
[30] Steven HS, Elias C, Nancy Lee H, Elaine SJ, Stefano AP. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. 4th ed. Lyon:International Agency for Research on Cancer, 2017:250-259.
[31] Sidlo J, Sidlova H. Sudden and unexpected death due to intracranial sellar extramedullary plasmacytoma[J]. J Forensic Leg Med, 2019, 61:89-91.
[32] Chowdhury D, Rahman A, Rashid MH, Chaurasia B, Kamal M, Barua KK. Primary non-hodgkin lymphoma of sphenoid sinus involving cavernus sinus and clivus with isolated 3rd nerve palsy[J]. Mymensingh Med J, 2018, 27:888-893.
[33] Vasiljevic A, Szathmari A, Champier J, Fèvre-Montange M, Jouvet A. Histopathology of pineal germ cell tumors[J]. Neurochirurgie, 2015, 61:130-137.
[34] Mufti ST, Jamal A. Primary intracranial germ cell tumors[J]. Asian J Neurosurg, 2012, 7:197-202.
[35] Ji X, Wang Z, Wang W, Gao L, Guo X, Feng C, Lian W, Deng K, Xing B. Clinical characteristics of pediatric patients with sellar and suprasellar lesions who initially present with central diabetes insipidus:a retrospective study of 55 cases from a large pituitary center in China[J]. Front Endocrinol (Lausanne), 2020, 11:76.
[36] Lobo J, Gillis AJM, Jerónimo C, Henrique R, Looijenga LHJ. Human germ cell tumors are developmental cancers:impact of epigenetics on pathobiology and clinic[J]. Int J Mol Sci, 2019, 20:258.
[37] Umbreit EC, Siddiqui BA, Hwang MJ, Joon AY, Maity T, Westerman ME, Merriman KW, Alhasson H, Uthup J, Guo T, Moore JA, Ward JF, Karam JA, Wood CG, Pisters LL, Zhang M, Tu SM. Origin of subsequent malignant neoplasms in patients with history of testicular germ cell tumor[J]. Cancers (Basel), 2020, 12:3755.
[38] Seifert K, Huttner A, Malhotra A. A rare case of a pediatric medullary intracranial germinoma[J]. World Neurosurg, 2020, 138:137-140.
[39] Matsutani M, Sano K, Takakura K, Fujimaki T, Nakamura O, Funata N, Seto T. Primary intracranial germ cell tumors:a clinical analysis of 153 histologically verified cases[J]. J Neurosurg, 1997, 86:446-455.
[40] Bowzyk Al-Naeeb A, Murray M, Horan G, Harris F, Kortmann RD, Nicholson J, Ajithkumar T. Current management of intracranial germ cell tumours[J]. Clin Oncol (R Coll Radiol), 2018, 30:204-214.
[41] Yu HH, Yonemura Y, Hsieh MC, Lu CY, Wu SY, Shan YS. Experience of applying cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian teratoma with malignant transformation and peritoneal dissemination[J]. Ther Clin Risk Manag, 2019, 15:129-136.
[42] Rathore R, Sharma S, Agarwal S. Malignant transformation in mature cystic teratoma of the ovary:a retrospective study of eight cases and review of literature[J]. Prz Menopauzalny, 2018, 17:63-68.
[43] Fassett DR, Couldwell WT. Metastases to the pituitary gland[J]. Neurosurg Focus, 2004, 16:E8.
[44] Kleinschmidt-DeMasters BK. Metastases to the pituitary gland:histological patterns of spread and review of the literature[J]. J Neuropathol Exp Neurol, 2021[.Epub ahead of print]
[45] Dou XL, Zhou N, Mai YL, Guan M, Sun Z, Gao X, Bai CM. Gastric cancer with pituitary metastasis presenting as symptomatic secondary adrenal insufficiency:a case report[J]. J Dig Dis, 2017, 18:369-372.
[46] Burkhardt T, Henze M, Kluth LA, Westphal M, Schmidt NO, Flitsch J. Surgical management of pituitary metastases[J]. Pituitary, 2016, 19:11-18.
[47] Gopan T, Toms SA, Prayson RA, Suh JH, Hamrahian AH, Weil RJ. Symptomatic pituitary metastases from renal cell carcinoma[J]. Pituitary, 2007, 10:251-259.
[48] Atallah-Yunes SA, Clark J, Samanani S, Soe M. Small cell lung cancer with pituitary metastasis presenting as secondary adrenal insufficiency:a case report and literature review[J]. Am J Case Rep, 2019, 20:207-211.
[49] Gilard V, Alexandru C, Proust F, Derrey S, Hannequin P, Langlois O. Pituitary metastasis:is there still a place for neurosurgical treatment[J]? J Neurooncol, 2016, 126:219-224.
[50] Zada G, Lopes MBS, Mukundan S Jr, Laws ER Jr. Metastatic tumors to the pituitary gland[M]//Atlas of sellar and parasellar lesions. Switzerland:Springer International Publishing, 2016:391-399.
[51] Nasr C, Mason A, Mayberg M, Staugaitis SM, Asa SL. Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma[J]. J Clin Endocrinol Metab, 2006, 91:4776-4780.

选择文件类型/文献管理软件名称

选择包含的内容

2 2017版WHO垂体非神经内分泌肿瘤分类临床指导及国际疾病分类法编码分析

The 2017 WHO classification and International Classification of Disease coding analysis of non-neuroendocrine tumors in the pituitary gland

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	佟志勇. 颅内动脉瘤与脑血管重建术[J]. 中国现代神经疾病杂志, 2024, 24(8): 595-598.
[2]	佟志勇. 脑血管重建术历史沿革[J]. 中国现代神经疾病杂志, 2024, 24(8): 599-605.
[3]	金凌骥, 胡俊文, 李寅, 王林. 复杂颅内动脉瘤的颅内-颅内血管搭桥术[J]. 中国现代神经疾病杂志, 2024, 24(8): 606-612.
[4]	刘佩玺, 史源, 朱巍. 血流导向时代颅内全域脑血管搭桥术治疗颅内动脉瘤之应用方略[J]. 中国现代神经疾病杂志, 2024, 24(8): 613-618.
[5]	张峰, 孟凡刚. 帕金森病自主神经功能障碍丘脑底核脑深部电刺激术治疗进展[J]. 中国现代神经疾病杂志, 2024, 24(7): 510-515.
[6]	吴桂智, 田宏. Meige综合征脑深部电刺激术治疗进展[J]. 中国现代神经疾病杂志, 2024, 24(7): 516-521.
[7]	孟凡刚, 张建国. 耳后磨骨槽技术在脑深部电刺激术中的应用[J]. 中国现代神经疾病杂志, 2024, 24(7): 522-524.
[8]	陈琳, 潘华. 功能性震颤的电生理诊断[J]. 中国现代神经疾病杂志, 2024, 24(7): 573-578.
[9]	魏俊吉, 常健博. 深入基层医院普及神经外科重症管理理念[J]. 中国现代神经疾病杂志, 2024, 24(6): 403-406.
[10]	史若琳, 高秀洁, 崔家宁, 邵妍, 谢璐霜, 刘毅. 5-羟色胺与帕金森病非运动症状研究进展[J]. 中国现代神经疾病杂志, 2024, 24(6): 497-501.
[11]	李海峰. 在进入靶向治疗的时代激素仍然是重症肌无力治疗的基础[J]. 中国现代神经疾病杂志, 2024, 24(5): 295-307.
[12]	许鸿嘉, 舒崖清, 王蘋, 李蕃, 许顺良, 邱伟, 马晓宇. 抗水通道蛋白4抗体阳性视神经脊髓炎谱系疾病诊断与治疗进展[J]. 中国现代神经疾病杂志, 2024, 24(5): 308-314.
[13]	黄瑀, 廖金池, 舒崖清. 抗N-甲基-D-天冬氨酸受体脑炎睡眠障碍研究进展[J]. 中国现代神经疾病杂志, 2024, 24(5): 315-319.
[14]	刘彩云, 金涛. 树突状细胞在多发性硬化免疫治疗中的应用[J]. 中国现代神经疾病杂志, 2024, 24(5): 320-330.
[15]	王军成, 赵岳阳, 杨强, 蒯涛, 潘亚文. HMGB1基因调控胶质瘤恶性生物学行为研究进展[J]. 中国现代神经疾病杂志, 2024, 24(5): 391-397.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 2017版WHO垂体非神经内分泌肿瘤分类临床指导及国际疾病分类法编码分析

The 2017 WHO classification and International Classification of Disease coding analysis of non-neuroendocrine tumors in the pituitary gland

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价